BioTech
DHR

Danaher to buy biotech company Aldevron for about $9.6 billion

Credit: REUTERS/Jose Luis Gonzalez

Medical equipment maker Danaher Corp said on Thursday it would buy privately held biotech company Aldevron in an all-cash deal for about $9.6 billion.

Adds details on deal

June 17 (Reuters) - Medical equipment maker Danaher Corp DHR.N said on Thursday it would buy privately held biotech company Aldevron in an all-cash deal for about $9.6 billion.

Danaher said it expects to finance the deal using cash on hand and/or proceeds from the issuance of commercial paper.

Aldevron produces plasmid DNA, mRNA and proteins to help biotechnology and pharmaceutical customers across research, clinical and commercial fields. The company also has a deal with COVID-19 vaccine maker Moderna Inc MRNA.O to supply plasmid DNA, which is required in vaccine making.

Aldevron will operate as a standalone company and brand within Danaher's Life Sciences segment, Danaher said.

(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila and Amy Caren Daniel)

((Dania.Nadeem@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

DHR MRNA

Other Topics

US Markets

Latest Technology Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More